spacer
home > ict > Spring 2016
PUBLICATIONS

International Clinical Trials

ict
Spring 2016

   
Text
PDF
Editor's Comment

Graham Hughes
introduces this issue by outlining the two sides of clinical trial data – transparency on the one hand, and protection on the other hand – among other topics.

 
view
download pdf
bullet
Clinical Trial Management
Site Activation

Head Start


First and foremost, each clinical trial needs to undergo site activation – which can be a lengthy and tiresome process, says Melissa Easy at DrugDev. There are, however, three models at hand using the most recent technology to help facilitate trial start-up.

 
view
download pdf
Paediatric Trials

On Your Doorstep


With paediatric trials becoming more common, Dr Graham Wylie at MRN states that home visits in particular are part of an increasingly patient-centric healthcare movement.


 
view
download pdf
bullet
MARKETPLACE
End Point

Activity Surge

Graham Hughes
reports on the increasing activity in M&A over the past few decades, and outlines reasons for merging and the implications for consumers and stakeholders.

 
view
download pdf
Marketing Applications

The Final Step


Representing the last hurdle in bringing a drug to market, marketing applications can be costly and time consuming to develop. Rho’s David Shoemaker presents different application models to facilitate this procedure.


 
view
download pdf
bullet
Regional trials
Regional Trials

Across the Globe


ICT takes a closer look at the clinical trial landscape in different markets – namely Latin America, the MENA region, Indonesia and finally, in the EU.

 
view
download pdf
Latin America

Susana Bule and Cláudia Carvalho at Eurotrials reveal that the Latin American market has been demonstrating great potential for clinical research and pharmaceutical development for some years now. The spending in healthcare has also been increasing, which shows the governments’ prioritisation of this matter.


 
view
download pdf
The Middle East and North Africa

Cellia Habita at ARIANNE explores clinical trials in the Middle East and North Africa, and explains why these areas should not be neglected in favour of more familiar countries.

 
view
download pdf
Indonesia

Rutger Oudejans at UBM EMEA highlights the importance of local expertise in Indonesian clinical trials, and describes why this region has gained significant value in pharma as a whole.

 
view
download pdf
European Union

Srikanth Venkataraman
at Frost & Sullivan explores patient recruitment for global clinical trials – with a focus on the EU – which he believes are going to be transformed by digital platforms and mobile technologies.

 
view
download pdf
bullet
data management & statistical analysis
Data Protection

Under Wraps

8MAN’s Jens Puhle
believes that keeping data safe from rival organisations and potential theft is paramount in pharma – with threats being closer to home than one might think.

 
view
download pdf
Clinical Trial Data

Access Denied

Graham Donaldson
at TRAC Services looks at the transparency of data versus the protection of commercially confident information in light of the latest regulations introduced to Europe.

 
view
download pdf
Data Analytics

The More, The Merrier


There is no doubt that data plays an important role in pharma – and with a growing focus on the patient in the form of personalised medicine and services, this role is set to further expand, states Wipro Ltd’s Nitin Raizada.

 
view
download pdf
Data Formatting

Preparing for SEND

Roman Radelicki
at SGS believes that implementing the standardised electronic format SEND can help streamline the process of submitting electronic data in non-clinical studies, and can further save time and money.

 
view
download pdf
bullet
Drug delivery & Therapeutics
Rare Disease Treatment

Making a Difference

World Courier’s Sue Lee
discusses the growing importance of orphan drugs, which must be produced in small quantities for a limited patient population, and questions the fact that only 5% of rare diseases have treatments available.

 
view
download pdf
bullet
Supply Chain & Manufacturing
Clinical Supply Chains

On Demand


Adaptive trial design is becoming increasingly popular, observes Catalent’s Dr Paul Ingram, before investigating its implications on supply chain efficiency.

 
view
download pdf
Logistics and Handling

Touch Point

Essangui Mbaitjongue
at Thermo King is convinced that with the help of tighter temperature guidelines, the shipment of pharmaceuticals can be facilitated – thus enabling them to reach their destination unharmed.

 
view
download pdf
bullet
Central Labs
Microbiological Labs

Driven by Results: Part 2


Olga Sazonova, Veronika Khokhlova, Maxim Belotserkovsky
and Andrey Karelin at PSI CRO continue examining quantitative urine culture studies, and consider country-specific differences.

 
view
download pdf

Cancer Therapeutics
Pharmacogenomics and Oncology

Special Treatment

United BioSource Corporation’s Dr Don Gabriel
outlines the implications of the use of pharmacogenomics – the study of individuals’ genetic variations – on oncology, and how that impacts the way patients respond to medication.


 
view
download pdf
Oncology Research

Relationships Matter

Dr Martin Lachs
at ICON examines the connection between sites and CROs when enrolling patients in oncology studies, and considers how to further improve this relationship.

 
view
download pdf
   
spacer


Published quarterly in
February, May,
August, and November

News and Press Releases

Cargo Convoy Departs to China Carrying Medical Supplies Donated by Qatar Airways for Coronavirus Relief

2,500,000 face masks and 500,000 bottles of hand sanitizer have been donated by Qatar Airways
More info >>

White Papers

Case Study: Cmed’s Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>

Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement